Friday, June 10, 2016

BRIEF-Bristol-Myers announces phase 2 data for Opdivo studies

* Says Opdivo demonstrated objective response rate of 66.3%

in classical Hodgkin lymphoma patients

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)